TRCT
CLBT icon

Tower Research Capital (TRC)’s Cellebrite CLBT Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$14 – 5260
2026
Q1 		$14 Buy
+1
New +$15 ﹤0.01% 5068
2025
Q4 		– Sell
-1,179
Closed -$21.8K – 5202
2025
Q3 		$21.8K Sell
1,179
-1,059
-47% -$16.6K ﹤0.01% 3237
2025
Q2 		$35.8K Buy
+2,238
New +$39.9K ﹤0.01% 3258
2025
Q1 		– Sell
-76
Closed -$1.67K – 5266
2024
Q4 		$1.67K Sell
76
-3,405
-98% -$65.5K ﹤0.01% 4984
2024
Q3 		$58.6K Sell
3,481
-31,536
-90% -$468K ﹤0.01% 2636
2024
Q2 		$418K Buy
35,017
+29,914
+586% +$334K 0.01% 1484
2024
Q1 		$56.5K Buy
+5,103
New +$52.1K ﹤0.01% 2189
2022
Q2 		– Sell
-596
Closed -$4K – 6112
2022
Q1 		$4K Buy
+596
New +$3.95K ﹤0.01% 5186
2021
Q4 		– Sell
-1,363
Closed -$13K – 6170
2021
Q3 		$13K Buy
+1,363
New +$14.2K ﹤0.01% 4068

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Tower Research Capital (TRC)'s CLBT Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Cellebrite (CLBT) in Q2 2026, closing a stake of 1 share — an estimated $14 sold.

Tower Research Capital (TRC) first reported a position in CLBT in Q3 2021 and held it in 9 quarters. The position peaked at $418K in Q2 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Cellebrite position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1 Cellebrite share in Q2 2026, an estimated $14.
  • Tower Research Capital (TRC) first reported a position in Cellebrite in Q3 2021 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Cellebrite position peaked at $418K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.